Antibody-cytokine fusion proteins for the therapy of cancer.
about
The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyLack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2.Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Strategies to endow cytotoxic T lymphocytes or natural killer cells with antibody activity against carcinoembryonic antigen.Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives.A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.Construction, expression, and characterization of a single-chain variable fragment antibody against 2,4-dichlorophenoxyacetic acid in the hemolymph of silkworm larvae.Current progress in innovative engineered antibodies.Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein.Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
P2860
Q28088784-3444E94A-673C-4E7C-B8FF-8C535F0AA4F5Q30835165-3F243B81-056C-4B60-9F4C-C9314DECB585Q34790338-8D80D570-CE69-4FC9-AA75-16C880CA41E5Q34996213-00578B61-4F4D-4A34-A23C-B4B507E93A8CQ35163167-95688906-AE1F-4F22-B201-8912C6ED977FQ35959307-4F54E073-14C2-40E0-B499-AADFA3A16546Q36438481-DAB181D4-4FC9-4C38-9C72-3E4F36693D28Q39156763-B5319100-3E9E-47D6-BEBF-7286053AD32BQ39600514-13F1EDFD-DF7B-4A8B-80B1-11A00EC35AFCQ40077818-5B0383FC-E2F3-4F41-8313-8926D1CCE372Q44640632-70488A8B-CE70-459A-B4F2-68AC87302A51Q44703429-6E7C5EDD-33BE-42BC-A9E7-786FFB82C674Q50885364-A1CFF567-D523-4EF9-A651-E54D68204305
P2860
Antibody-cytokine fusion proteins for the therapy of cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antibody-cytokine fusion proteins for the therapy of cancer.
@ast
Antibody-cytokine fusion proteins for the therapy of cancer.
@en
Antibody-cytokine fusion proteins for the therapy of cancer.
@nl
type
label
Antibody-cytokine fusion proteins for the therapy of cancer.
@ast
Antibody-cytokine fusion proteins for the therapy of cancer.
@en
Antibody-cytokine fusion proteins for the therapy of cancer.
@nl
prefLabel
Antibody-cytokine fusion proteins for the therapy of cancer.
@ast
Antibody-cytokine fusion proteins for the therapy of cancer.
@en
Antibody-cytokine fusion proteins for the therapy of cancer.
@nl
P1476
Antibody-cytokine fusion proteins for the therapy of cancer.
@en
P2093
Morrison SL
Penichet ML
P304
P356
10.1016/S0022-1759(00)00345-8
P577
2001-02-01T00:00:00Z